Eli Lilly and Company

Antonio Navarro

David Andrew Coates

Russell Dean Stucky

Nathan Bryan Mantlo

Tianwei Ma

Steven Marc Massey

Miles Goodman Siegel

Lance Allen Pfeifer

Douglas Linn Gernert

Ashraf Saeed

Jason Kenneth Myers

Kevin Charles Fortner

The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.

CGRP receptor antagonists

The present invention is directed to compounds represented by the following structural formula, Formula (I): wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) W is N, O or S; (e) E is C(R3)(R4)A or A and wherein; (f) A is selected from the group consisting of carboxyl, tetrazole, C-Calkylnitrile, carboxamide, sulfonamide and acylsufonamide. The other substituents are defined in the claims; the compounds are modulators of peroxisome proleferator activated receptors (PPARs) and are useful for the treatment of diabetes and other metabolic disorders.

Triazole PPAR modulators

Growing community of inventors

Indianapolis, IN, United States of America

Antonio Navarro